Active Ingredient History
A CDK inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. While there are multiple cyclin/CDK complexes regulating the cell cycle, CDK inhibitors targeting CDK4/6 have been the most successful, with 4 CDK4/6 inhibitors haven been FDA approved. No inhibitors targeting other CDKs have been FDA approved, but several compounds are in clinical trials. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Small Cell (approved 2021)
Bone Marrow Diseases (Phase 3)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Colorectal Neoplasms (Phase 3)
Healthy Volunteers (Phase 1)
Lung Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 4)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
